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Objectives: Guidelines for hepatitis C (HCV) strongly recommend antiviral treatment for 
patients with more severe liver disease given their increased risk of developing cirrhosis and 
other liver-related complications. Despite the proven benefits of therapy, 70%–88% of patients 
chronically infected with HCV do not undergo treatment. The goal of this paper is to describe 
patterns of treatment initiation among patients with both mild and severe disease and to assess 
the factors that are associated with treatment initiation and completion.
Methods: Subjects completed previously validated questionnaires to ascertain sociodemo-
graphic characteristics, choice predisposition, and clinical characteristics prior to meeting 
with the hepatologist to discuss treatment initiation and were followed for 12 months. We 
examined the association between patient characteristics and treatment patterns controlling for 
liver disease severity.
Results: Of the 148 eligible subjects entered into our study, 55 (37%) initiated treatment 
during the 12-month follow-up period. Of the 86 subjects with severe liver disease, 43 (50%) 
initiated treatment. Financial barriers and geographic access to care were the most common 
reasons for treatment deferral. Of the 55 patients initiating treatment, 24 (44%) discontinued 
treatment, with intolerance of side effects being the most common reason for discontinuation. 
After adjusting for liver disease severity, patient choice predisposition (prior to discussion with 
their provider) was strongly associated with initiation of treatment, while sociodemographic 
characteristics were not.
Conclusion: Treatment initiation did align with current recommendations (patients with 
severe disease were more likely to initiate treatment), however, rates of treatment initiation 
and completion were low. Patient choice predisposition is the strongest predictor of treatment 
initiation, independent of disease severity. Improving individualized treatment outcomes for 
patients with chronic HCV requires efforts at identifying patients’ choice predisposition, and 
improving access for those wishing to initiate therapy.
Keywords: barriers, access, preferences, utilization, adverse events
Introduction
Hepatitis C (HCV) is a major public health burden with an estimated 180 million 
people infected worldwide.1 Data from the National Health and Nutrition Exami-
nation   Survey (Centers for Disease Control and Prevention, Atlanta, GA) between 
1999 and 2002 estimate a prevalence of HCV infection of 1.6% in the US popula-
tion, affecting more than 4 million Americans.2 US veterans are disproportionately 
affected, with a seroprevalence of 5.4%.3 Up to 22% of patients with chronic HCV will 
develop cirrhosis over 20 years.4 Patients that develop cirrhosis are at risk for hepatic 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
285
OrIGINAL rESEArCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S30111Patient Preference and Adherence 2012:6
decompensation (30% over 10 years) and development of 
hepatocellular carcinoma (1%–3% per year).5 Chronic HCV 
infection is associated with both increased liver-related and 
overall mortality.6
Sustained virological response (SVR) to treatment 
decreases progression to cirrhosis and incidence of hepato-
cellular carcinoma and improves survival.7–9 At the time of 
this study protocol, standard treatment for HCV consisted 
of the combination of pegylated interferon and ribavirin, 
which yields SVR in roughly 50% of patients.1,10 As of 
October 2011, new guidelines recommend the addition of 
a protease inhibitor (boceprevir or telaprevir) to previous 
standard therapy.11 Triple therapy regimens such as these 
yield SVR ranging from 67%–76% in treatment-naïve 
patients.12–17 However, despite the proven benefits of therapy, 
70%–88% of patients chronically infected with HCV do not 
undergo treatment.18–22
Consensus panels suggest that patient preferences 
guide treatment decisions in patients with mild disease.1,23 
In contrast, guidelines strongly recommend antiviral 
treatment for patients with more severe disease (portal 
or bridging fibrosis and moderate inflammation on liver 
biopsy) given their increased risk of developing cirrhosis 
and other liver-related complications.1,23 Among treatment-
eligible patients, the most common reason for not initiating 
therapy is patient refusal.18–22 Treatment efficacy is further 
limited by intolerance to side effects, with treatment dis-
continuation rates secondary to adverse events as high as 
21%.10,12–17,24,25
To the best of our knowledge, no studies have evaluated 
the barriers and specific patient characteristics that are associ-
ated with failure to initiate treatment or discontinuation of 
treatment in well-informed, motivated, and treatment-eligible 
patients with chronic HCV . Moreover, previous studies have 
not distinguished between those with mild and those with 
more severe liver disease. Understanding the specific factors 
influencing patients’ decisions regarding treatment initiation, 
deferral, and discontinuation are central to improving the 
outcomes of this widespread disease.
In this study, we followed treatment-naïve patients who 
met eligibility criteria and were being offered pegylated 
interferon and ribavirin for chronic HCV over the course 
of 12 months. The goal of this paper is to describe patterns 
of treatment initiation among patients with both mild and 
severe disease and to assess the factors that correlate with 
treatment initiation and completion, particularly among 
patients with severe disease for whom treatment is strongly 
recommended.
Subjects and methods
Subjects
The study was conducted at two sites: the Yale University 
School of Medicine Liver Clinic (New Haven, CT), and the 
Veterans Administration (VA) Connecticut Healthcare System 
Liver Clinic (West Haven, CT). The same hepatologists attend 
both clinics. Consecutive patients eligible for treatment of 
HCV were recruited. Eligibility criteria included treatment-
naïve patients with chronic HCV of a known genotype, and 
either clinical evidence of cirrhosis or a liver biopsy within the 
preceding 2 years. Inclusion criteria were based on recommen-
dations from the National Institutes of Health (NIH), American 
Association for the Study of Liver Diseases (AASLD), and 
the VA at the time of the study which stated that patients with 
chronic HCV and evidence of chronic hepatitis on liver biopsy 
should be offered therapy with the combination of pegylated 
interferon and ribavirin regardless of genotype or the presence 
of symptoms.1,23,26 Exclusion criteria were conditions that are 
considered contraindications to therapy, specifically: major 
uncontrolled depression, solid organ transplant, an autoimmune 
disorder that could be exacerbated by interferon, untreated 
thyroid disease, pregnancy or unwillingness to comply with 
contraception, and marked anemia or known hypersensitivity 
to pegylated interferon or ribavirin.1,23,26 Subjects were recruited 
by the treating physician, advanced practice registered nurse, 
or the research nurse at the time of liver biopsy appointment. 
Subjects who did not have a scheduled liver biopsy were invited 
to participate by clinic staff and consented by the research 
nurse on the day of their study visit.27 Liver fibrosis was staged 
according to the Batts and Ludwig classification28 (a modifica-
tion of the Scheuer classification) in which Stage 0 corresponds 
to no fibrosis, Stage 1 is portal fibrosis, Stage 2 is periportal 
fibrosis, Stage 3 is bridging fibrosis, and Stage 4 is cirrhosis. 
Prior to ascertaining baseline data, all subjects participating in 
this study underwent a formalized education class regarding 
the disease, its natural history, course and treatment options, 
and their side effects. They were also informed of the stage 
of their disease. Subsequently, baseline data were collected, 
followed directly by the initial visit with their hepatologist to 
discuss treatment initiation.
All participants completed written informed consent. The 
protocol was approved by the Human Subjects Subcommittee 
of the VA Connecticut Healthcare System and by the Yale 
School of Medicine.
Data collection
All data were collected in a private room with the help of a 
research nurse. All subjects completed previously validated 
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questionnaires to ascertain sociodemographic   characteristics, 
alcohol and drug use,29–31 social support,32 overall health 
status,33 trust in physician,34 and physical, social, and 
emotional impact of HCV (quality of life scale).35 Medical 
comorbidities were defined based on patients’ responses to 
a predefined list of six conditions: hypertension, diabetes, 
lung disease, kidney disease, peptic ulcer disease, or mental 
illness.36 Depression was measured using a two question 
instrument that evaluates depressed mood and anhedonia. 
This instrument has been validated in a VA setting against 
six other instruments.37 Baseline choice predisposition was 
ascertained based on a previously validated scale ranging 
from zero (I am certain that I do not want to be treated) 
to ten (I am certain that I do want to be treated).38 In this 
study, choice predisposition reflects patient preference for 
treatment measured prior to completing a decision support 
tool and prior to meeting with their hepatologist to discuss 
initiation of treatment.
Baseline data were collected in a face-to-face interview 
prior to the patient–physician visit during which treatment 
initiation was discussed. Follow-up data was collected in 
telephone interviews conducted 1, 3, 6, and 12 months later. 
Up to three attempts were made to contact each subject at 
each time point. During follow-up interviews the research 
assistant elicited patients’ initial treatment decision, their 
treatment decision at the time of the interview, and whether 
they had initiated treatment. Reasons for not having initiated 
treatment and whether treatment was continuing, completed, 
or discontinued were also documented.
Statistical analysis
Subject characteristics and survey data were entered into 
SAS computer files (SAS software, v 9.2; SAS Institute Inc, 
Cary, NC). Age, social support, HCV-related quality of life, 
trust in physician, and choice predisposition were treated as 
continuous variables. The remaining characteristics were 
treated as categorical variables. Health status was categorized 
as excellent or very good versus good, fair or poor. Severity of 
liver disease was categorized as mild (fibrosis Stages 0–2) or 
severe (fibrosis Stages 3–4 and/or clinical cirrhosis). Alcohol 
and drug use were classified as ever versus never use.
Using descriptive statistics we reported subjects’ choice 
predisposition (treatment preference prior to discussing 
treatment initiation with their hepatologist), intent to initi-
ate treatment after discussion with their hepatologist, the 
number of subjects that actually initiated treatment, and of 
those that initiated treatment, the number that discontinued 
treatment.
We then examined the association between patient 
characteristics and treatment patterns using the Mann–Whitney 
U-test and the χ2 statistic for continuous and categorical 
variables, respectively. We compared sociodemographic 
and clinical characteristics among: (1) patients that initi-
ated treatment versus those that did not initiate treatment; 
(2) patients with severe disease that initiated treatment versus 
did not initiate treatment; and (3) patients that completed 
treatment versus those that did not complete treatment.
Results
Subject characteristics
Of  212 eligible subjects, 178 agreed to participate in the 
study, and 148 completed the baseline and subsequent 
follow-up surveys. Thirty subjects did not complete base-
line surveys for logistical reasons as previously described.27 
Ninety-three percent of subjects completed two or more 
follow-up interviews over the 12-month period, and 93% 
completed interviews at least 3 months from the baseline 
interview.
Characteristics for subjects grouped by underlying 
liver disease severity are described in Table 1. The mean 
(±SD) age of the sample was 51 ± 8 years, 87% were male, 
45% were non-Hispanic white, and 34% were black. The 
median HCV-related quality of life score was 19 with range 
of  0–89 (possible range 0–100 with higher scores indicating 
poorer quality of life). Twenty percent reported excellent or 
very good health status. Sixty-two (42%) had mild liver dis-
ease (fibrosis Stages 0–2) and 86 (58%) had severe disease 
(fibrosis Stages 3–4, and/or clinical cirrhosis).
Choice predisposition
Prior to meeting with their hepatologist, subjects’ median 
choice predisposition score was seven with a range of 0–10. 
Higher scores represent greater preference towards under-
going treatment. Subjects with mild versus severe disease 
had median choice predisposition scores of five and eight, 
respectively (P = 0.007).
Treatment initiation
After completing a decision support tool and meeting with their 
hepatologist, 83 subjects (56%) reported that they intended 
to initiate treatment, 48 (32%) reported that they declined 
treatment, and 17 (12%) were undecided. Of the 83 subjects 
intending to undergo treatment, 33 (40%) had not initiated 
treatment by month 12. Twenty-four of these subjects (73%) 
had severe disease. Among the 48 subjects that reported 
declining treatment, none had initiated treatment by month 12. 
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Of these, 31% had severe disease. Treatment initiation patterns 
by disease severity are further detailed in Figure 1.
Reasons for not initiating treatment among subjects 
who had initially intended to undergo treatment are listed 
in Table 2. Financial barriers and geographic access to 
care were the most common reasons for treatment deferral. 
Some subjects changed their mind regarding their desire 
for treatment and others remained undecided during the 
follow-up period. Some reported that their work or school 
responsibilities made it difficult to find the right time to 
initiate treatment. Three subjects reported that they had 
failed to follow-up with the clinic in order to initiate treat-
ment. Seven subjects did not specify a reason for treatment 
deferral.
Course among subjects initiating 
treatment
Details of treatment course by disease severity are described 
in Figure 2. Fifty-five of 148 eligible subjects (37%) initiated 
treatment for HCV during the 12-month follow-up period. 
Forty-three (78%) of these subjects had severe disease. 
Of the 55 subjects who started treatment, 24 (44%) dis-
continued therapy during the follow-up period, of whom 
18 (75%) reported that treatment was discontinued by their 
physician while the remaining six subjects (25%) elected 
to discontinue treatment, most commonly because of per-
sistent side effects. None of these subjects reinitiated treat-
ment after discontinuation. Toxicity was the most common 
reason for discontinuing treatment overall, whereas a lack 
Table 1 Subjects’ characteristics by disease severity (N = 148)
Characteristic Mild disease  
Number (%)
Severe disease 
Number (%)
All patients 
Number (%)
Total number (%) 62 (42) 86 (58) 148 (100)
Age (mean, SD) 51 ± 8 52 ± 8 51 ± 8
Male 54 (87) 74 (86) 128 (87)
Hispanic 8 (13) 12 (14) 20 (14)
race
  White (non-Hispanic) 32 (52) 35 (41) 67 (45)
  Black 16 (26) 34 (40) 50 (34)
Married 16 (26) 20 (23) 36 (24)
At least some college education 34 (55) 33 (38) 67 (45)
Income .$60,000 5 (8) 3 (4) 8 (5)
Employed 26 (42) 31 (36) 57 (39)
Veteran clinic 49 (79) 49 (57) 98 (66)
Number of medical comorbiditiesa
  Zero 18 (29) 23 (27) 41 (28)
  One 26 (42) 33 (38) 59 (40)
  Two or more 18 (29) 30 (35) 48 (32)
Excellent or very good overall health statusb 16 (26) 13 (15) 29 (20)
HCV-related quality of lifec (median, range) 17 (0–89) 21 (0–89) 19 (0–89)
Trust in physiciand (median, range) 73 (45–100) 70 (45–100) 70 (45–100)
Patient choice predispositione (median, range) 5 (0–10) 8 (0–10) 7 (0–10)
HCV genotype 1 52 (84) 73 (85) 125 (85)
HCV genotype 2 10 (16) 13 (15) 25 (16)
Alcohol abuse
  Never 18 (29) 34 (40) 52 (35)
  Ever 44 (71) 52 (61) 96 (65)
  Current 2 (3) 5 (6) 7 (5)
Substance abuse
  Never 6 (10) 14 (16) 20 (14)
  Ever 56 (90) 72 (84) 128 (87)
  Current 6 (10) 5 (6) 11 (7)
History of depressionf 31 (50) 53 (62) 84 (57)
Notes: aBased on subjects’ response to a predefined list of six comorbidities: hypertension, diabetes, lung disease, kidney disease, peptic ulcer disease, and mental illness; 
bbased on subjects’ response to a validated questionnaire: (In general, I would say that my health is … poor, fair, good, very good or excellent); cbased on a previously 
validated hepatitis C (HCV) quality of life scale encompassing eleven questions. Range of total score is 0–100 with higher scores representing worse quality of life; dbased on 
a previously validated trust in physician scale. Range of total score is 0–100 with higher scores representing greater trust in physician; echoice predisposition was ascertained 
based on a previously validated scale ranging from zero (I am certain that I do not want to be treated) to ten (I am certain that I do want to be treated). Higher scores 
reflect greater preference towards undergoing treatment; fdepression was measured using a previously validated two-question instrument that evaluates depressed mood 
and anhedonia.
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of viral response was the most common reason physicians 
discontinued treatment (Table 3).
Patterns based on liver disease severity
Among the 62 subjects with mild disease, 20 (32%) reported 
that they intended to initiate treatment and 12 (19%) actu-
ally initiated treatment within 12 months of follow-up. 
Of these, five (42%) discontinued treatment. Among the 
86 subjects with severe disease, 63 (73%) reported that they 
intended to initiate treatment and 43 (50%) actually initiated 
treatment. Of these, 19 (44%) discontinued treatment.
relationship of subject characteristics 
and treatment patterns
The association between subject characteristics and ini-
tiation of treatment is described in Table 4A (categorical 
variables) and Table 4B (continuous variables). In bivariate 
analysis, we found that liver disease severity and choice 
predisposition were associated with initiation of treatment 
among all patients. HCV-related quality of life and age were 
borderline associated with initiation of treatment among 
all patients. In subjects with severe liver disease, only 
choice predisposition remained associated with initiation 
of treatment (Table 4A and B). We found no association 
between treatment initiation and age, genotype, gender, 
race, employment or marital status, education, history of 
depression, substance abuse, site of care, health status, 
trust in physician, HCV-related quality of life or social 
support score.
Associations between subject characteristics and comple-
tion of treatment are described in Table 5A (categorical 
variables) and Table 5B (continuous variables). Being married 
was the only factor associated with treatment completion. 
No other factors were associated with treatment completion, 
including genotype, disease severity, choice predisposi-
tion, HCV-related quality of life, trust in physician, history 
of depression or substance abuse, and sociodemographic 
characteristics.
Discussion
We found that in a population of treatment-eligible patients 
with chronic HCV, a relatively small proportion initiated 
treatment with pegylated interferon and ribavirin, and far 
fewer completed the course of therapy, within 12 months 
of follow-up. Of significant concern was that a substantial 
proportion of patients with severe liver disease (fibrosis 
Stages 3 or 4 or clinical cirrhosis) refused therapy or failed 
to initiate treatment. Of those with severe disease, only 28% 
Table 2 Patient-reported reasons for not initiating treatment in 
patients that initially expressed intent to undergo treatment
All patients 
(n = 33)
Severe disease 
(n = 24)
Financial/insurance 7 5
Transportation/geographic access 7 5
Decided against treatment 5 2
Timinga 5 4
Missed appointments/no follow-up 3 2
Medical comorbidities 3 1
Indecision with regard to  
treatment preference
2 0
Unstable living situation or  
inadequate support
1 1
Transplant-listed  
(ineligible for treatment)b
1 1
Notes: aPostponing treatment until able to optimize timing in regards to school, work 
or other issues;  bthis subject developed decompensation and became transplant-
listed after enrollment. Some subjects provided more than one response.
Figure 1 Treatment initiation patterns in 148 patients with chronic hepatitis C by disease severity from initial survey (after discussion with hepatologist) to follow-up after 
12 months.
Notes: Mild liver disease defined by fibrosis Stages 0–2. Severe liver disease defined by fibrosis Stages 3–4 and/or clinical cirrhosis.
Intent to initiate
treatment
Never initiated
treatment
Initiated
treatment
Mild = 11 (21%)
Mild = 20 (24%)
Severe = 39 (78%)
Mild = 9 (27%)
Severe = 24 (73%)
Severe = 63 (76%)
N = 33 (40%)N  = 50 (60%)
N = 83
Undecided
Never initiated
treatment
Initiated
treatment
Mild = 1 (20%)
Mild = 9 (53%)
Severe = 4 (80%)
Mild = 8 (67%)
Severe = 4 (33%)
Severe = 8 (47%)
N = 12 (71%)N  = 5 (29%)
N = 17
Declined
treatment
Never initiated
treatment
Mild = 33 (69%)
Severe = 15 (31%)
Mild = 33 (69%)
Severe = 15 (31%)
N = 48
N = 48 (100%)
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completed a course of therapy. Treatment patterns did align 
with current treatment recommendations (disease severity 
was positively associated with initiation of treatment). 
However, this study highlights the persistence of suboptimal 
treatment initiation and completion patterns particularly in 
patients with advanced disease. This is also the first study 
documenting that patient choice predisposition is a strong pre-
dictor of treatment initiation, independent of disease severity. 
We would argue that with currently available therapies, 
optimization of treatment for hepatitis C requires attention 
to both the evaluation of patients’ choice predisposition, and 
the reduction of barriers to treatment initiation.
While there is generally low uptake and completion of 
therapy in HCV , it is most important to be able to identify 
patients with severe disease who are at higher risk for failing 
to initiate treatment. In this study, we found a strong associa-
tion between patient choice predisposition and initiation of 
treatment, independent of underlying liver disease severity. 
This finding may support the practice of measuring choice 
predisposition (using a previously validated eleven-point 
Initiated
treatment
Continuing or
completed treatment Discontinued treatment
Physician discontinued
Patient
discontinued
N = 3 (5%)
N = 18 (75%)
N = 6 (25%)
N = 24 (44%) N = 28 (51%)
Severe = 43 (78%)
Severe = 3 (100%)
Mild = 12 (22%)
Severe = 5 (83%) Severe = 14 (78%)
Severe = 19 (79%)
Severe = 21 (75%)
Mild = 5 (21%)
Mild = 4 (22%) Mild = 1 (17%)
Mild = 7 (25%)
Mild = 0
N = 55
Inadequate
dataa
Figure 2 Treatment completion patterns in 55 patients who initiated treatment by disease severity over the course of 12 months.
Notes: aSubjects gave no reason for not initiating treatment and completed two or fewer follow-up surveys, including no follow-up at 6 month or 12 month surveys. Mild liver 
disease defined by fibrosis Stage 0–2. Severe liver disease defined by fibrosis Stages 3–4 and/or clinical cirrhosis.
Table 3 Patient-reported reasons for discontinuing treatment
Physician discontinued (n = 18) Patient discontinued (n = 6)
Lack of viral response 5 Side effects/Intolerance 4
Severe side effects 4 Insurance 1
Social factors 2 Social factors 1
Medical comorbidities 1 No specific reason given 1
Non-compliance 1
No specific reason given to patient 7
Note: Some subjects provided more than one response.
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Table 4A Associations between subject characteristics (categorical) and initiation of treatment
Characteristic All patients  
(N = 148)
Patients with severe disease  
(N = 86)
Percentage initiating  
treatment (N)
P value Percentage initiating  
treatment (N)
P value
race
  Non-Hispanic white 31 (21) 0.18 43 (15) 0.27
  Other 42 (34) 55 (28)
Gender
  Male 36 (46) 0.44 49 (36) 0.53
  Female 45 (9) 58 (7)
Education
  Some college 34 (23) 0.52 48 (16) 0.83
  No college 40 (32) 51 (27)
Marital status
  Married 36 (13) 0.88 45 (9) 0.61
  Unmarried 38 (42) 52 (34)
Employment status
  Employed 35 (20) 0.68 48 (15) 0.82
  Unemployed 38 (35) 51 (28)
History of depressiona
  Yes 38 (26) 0.80 44 (19) 0.28
  No 36 (29) 56 (24)
Alcohol abuse
  Ever 36 (35) 0.81 52 (27) 0.66
  Never 38 (20) 47 (16)
Substance abuse
  Ever 38 (48) 0.83 54 (39) 0.08
  Never 35 (7) 29 (4)
Site of care
  Veteran 36 (35) 0.61 53 (26) 0.51
  Nonveteran 40 (20) 46 (17)
Health statusb
  Excellent/very good 34 (10) 0.74 38 (5) 0.37
  Good/fair/poor 38 (45) 52 (38)
Number of comorbiditiesc
  Two or more 40 (19) 0.67 57 (17) 0.37
  Less than two 36 (36) 46 (26)
Genotype
  One 37 (44) 0.34 48 (35) 0.37
  Two 48 (11) 62 (8)
Liver disease severityd (fibrosis stage)
  Severe 50 (43) ,0.01 N/A –
  Mild 19 (12) N/A
Notes: aDepression was measured using a previously validated two-question instrument that evaluates depressed mood and anhedonia; bbased on subjects’ response to a 
previously validated questionnaire: (In general, I would say that my health is … poor, fair, good, very good or excellent); cbased on subjects’ response to a predefined list of 
six comorbidities: hypertension, diabetes, lung disease, kidney disease, peptic ulcer disease, and mental illness; dstaged according to the Batts and Ludwig classification.29 Mild 
disease defined as fibrosis Stages 0–2. Severe disease defined as fibrosis Stages 3–4 and/or clinical cirrhosis.
numeric rating scale)38 in clinical practice. This simple 
screening tool could be used to identify patients with severe 
disease who are at higher risk of not initiating treatment and 
may benefit from more targeted education strategies or sup-
port. We found no significant association between treatment 
initiation and sociodemographic characteristics including 
HCV-related quality of life, when controlling for liver disease 
severity. Ultimately, identifying the specific factors that drive 
patient preference or choice predisposition may allow for the 
development of more targeted interventions to increase the 
number of eligible patients initiating therapy.
Despite the extensive education provided at both sites, 
one-quarter of patients with severe disease declined treatment 
even after discussion with their hepatologist. This suggests 
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Table 4B Associations between subject characteristics (continuous) and initiation of treatment
Characteristic All patients median (range) Patients with severe disease median (range)
Subjects initiating  
treatment (N = 55)
Subjects not initiating  
treatment (N = 93)
P value Subjects initiating  
treatment (N = 43)
Subjects not initiating  
treatment (N = 43)
P value
Age (years) 51 (26–64) 53 (23–70) 0.05 51 (26–64) 53 (36–70) 0.11
Social support scorea 67 (18–100) 64 (5–100) 0.56 64 (18–100) 68 (5–100) 0.95
HCV-related quality of lifeb 30 (0–77) 14 (0–89) 0.05 25 (0–77) 18 (0–89) 0.61
Trust in physicianc 73 (45–100) 70 (45–100) 0.41 73 (45–100) 66 (45–100) 0.18
Choice predispositiond 10 (3–10) 5 (0–10) ,0.01 10 (3–10) 5 (0–10) ,0.01
Notes: aBased on a previously validated social support scale consisting of 18 questions. Range of total score is 0–100 with higher scores representing greater social support; 
bbased on a previously validated hepatitis C (HCV) quality of life scale encompassing eleven questions. range of total score is 0–100 with higher scores representing worse 
quality of life; cbased on a previously validated trust in physician scale. Range of total score is 0–100 with higher scores representing greater trust in physician; dchoice 
predisposition was ascertained based on a previously validated scale ranging from zero (I am certain that I do not want to be treated) to ten (I am certain that I do want to 
be treated). Higher scores reflect greater preference towards undergoing treatment.
that patient education alone is insufficient to motivate a 
significant number of patients with severe disease to accept 
pegylated interferon and ribavirin for chronic HCV . Further 
studies will determine whether uptake is higher with triple 
therapy. Although most of the participants (56%) reported 
their intent to initiate treatment after seeing their hepatolo-
gists, only 55 of 148 (37%) actually initiated treatment within 
the 12 months. Current guidelines from the NIH, AASLD, 
and VA recommend treatment for all eligible patients with 
moderate or severe disease, while individualizing treatment 
plans for patients with mild disease.1,23,26 In our study, only 
50% of patients with severe disease initiated treatment, indi-
cating suboptimal treatment initiation rates among patients 
most in need of treatment.
Our results are consistent with previous studies citing low 
treatment rates, with only 11.8%–30% of patients chronically 
infected with HCV undergoing treatment.18–22,39 However, in 
contrast to our approach, these studies included patients that 
they considered ineligible for treatment such as patients with 
active substance abuse, psychiatric comorbidities, advanced 
cirrhosis, normal liver function tests, or an undetectable viral 
load. These studies also did not stratify by disease severity. 
In our study we included only patients that we considered 
eligible for treatment, who underwent intensive education 
about chronic HCV , its complications and treatment, and had 
already followed up with a liver specialty clinic. Moreover, 
many of our study patients had access to the Hepatitis C 
Resource Center at the VA Connecticut Health System, which 
is a multidisciplinary team dedicated to treating patients 
with active psychiatric and substance abuse comorbidities. 
This method of individualizing care for these patients 
with relative, not absolute, contraindications to treatment 
would be expected to improve the ability to capture more 
individuals as “suitable” candidates for treatment. Despite 
the abundance of patient support and education, and the 
exclusion of treatment-ineligible patients from our study, 
we found that only a minority of patients initiated treatment. 
These results indicate that there are significant barriers to 
initiating treatment beyond screening and education.
Reasons for not initiating treatment in our subjects fell 
into two major categories, system factors and patient-driven 
factors. System factors included geographic barriers (inabil-
ity to arrange transportation to appointments or to find a 
provider within a reasonable distance), financial limitations, 
and inadequate insurance coverage. Financial concerns 
were a significant barrier even in the veteran population, 
where non-service connected veterans have to pay $9 for 
each prescription and $50 copayment for each specialty 
clinic visit. The most common patient factors reported by 
the subjects in this study included that they had missed 
their appointments, had difficulty arranging sufficient time 
away from their responsibilities (eg, family, school, work) 
to commit to treatment, and had continued uncertainty 
regarding the risk-benefit tradeoffs of currently available 
therapies. System factors predominated for subjects with 
severe disease. These results suggest that interventions 
aimed at reducing geographic and financial barriers may 
increase the number of patients with severe disease willing 
to initiate therapy.
In addition to suboptimal treatment initiation rates, 
treatment completion rates were also low (19% overall at 
12 months) among our population within the 12 months 
of our study. Half of the patients that initiated treatment 
either discontinued treatment or were lost to follow-up. 
These   discontinuation rates are similar to other cited studies 
of non-clinical trial patients.20,39,40 Our results are also 
consistent with studies showing poorer treatment response 
rates in patients with genotype 1, severe liver disease, and 
age greater than 40 years; characteristics that predominated 
among subjects in this study who initiated treatment.10,41,42
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Table 5A Associations between subject characteristics (categorical) 
and completion of treatment
Characteristic Percentage  
completing  
treatment (N)
P value
race
  Non-Hispanic white 45 (9) 0.31
  Other 59 (19)
Gender
  Male 57 (25) 0.31
  Female 38 (3)
Education
  Some college 59 (13) 0.52
  No college 50 (15)
Marital status
  Married 83 (10) 0.02
  Unmarried 45 (18)
Employment status
  Employed 42 (8) 0.20
  Unemployed 61 (20)
History of depressiona
  Yes 58 (14) 0.55
  No 50 (14)
Alcohol abuse
  Ever 56 (18) 0.66
  Never 50 (10)
Substance abuse
  Ever 53 (24) 0.85
  Never 57 (4)
Site of care
  Veteran 52 (17) 0.66
  Nonveteran 58 (11)
Health statusb
  Excellent/very good 50 (5) 0.79
  Good/fair/poor 55 (23)
Number of comorbiditiesc
  Two or more 47 (9) 0.48
  Less than two 58 (19)
Genotype
  One 59 (24) 0.19
  Two 36 (4)
Liver disease severityd (fibrosis stage)
  Severe 53 (21) 0.72
  Mild 58 (7)
Notes:  aDepression  was  measured  using  a  previously  validated  two-question 
instrument  that  evaluates  depressed  mood  and  anhedonia;  bbased  on  subjects’ 
response to a previously validated questionnaire: (In general, I would say that my 
health is … poor, fair, good, very good or excellent); cbased on subjects’ response 
to a predefined list of six comorbidities: hypertension, diabetes, lung disease, kidney 
disease, peptic ulcer disease, and mental illness; dstaged according to the Batts and 
Ludwig classification.29 Mild disease defined as fibrosis Stages 0–2. Severe disease 
defined as fibrosis Stages 3–4 and/or clinical cirrhosis.
Most of our patients had treatment discontinued by their 
hepatologist because of drug-related toxicity or lack of viral 
response. Only six patients self-discontinued treatment, 
mainly due to inability to tolerate side effects. Factors that 
were associated with initiation of treatment (namely disease 
severity and choice predisposition) appeared to have no 
association with completion of treatment. Similarly, the sole 
factor correlating with treatment completion (marital status) 
had no association with treatment initiation. While not exam-
ined directly in our study, previous studies have shown the 
addition of telaprevir or boceprevir to pegylated interferon 
and ribavirin to be associated with similar or increased rates 
of adverse events, with discontinuation rates of 7%–21% 
for triple-therapy regimens.12–17,25 These results suggest that 
success rates with currently available drugs will continue to 
be limited despite efforts to improve screening for HCV and 
uptake of therapy. Improving the efficacy and tolerability of 
medication classes will be most crucial to optimize treatment 
completion rates.
To the best of our knowledge, this is the first study of its 
kind evaluating both patient preferences immediately prior 
to discussion about treatment initiation with the patients’ 
treating hepatologist, and patient treatment patterns over 
time. Other strengths include the exclusion of patients that 
were not eligible for HCV treatment and the stratification 
of patients based on liver disease severity. There are also 
important limitations to note. Although we recruited patients 
from both university and VA-based clinics, the majority 
were from the VA clinics. Thus, our study participants 
may not be fully representative of other samples that are 
community-based. Because our study examined pegylated 
interferon- and ribavirin-based regimens, generalizability 
to newer triple therapy regimens may be limited. However, 
the barriers to treatment initiation elucidated in this paper 
remain independent of the addition of these new medications. 
Additionally, triple therapy regimens as they currently stand 
continue to include both pegylated interferon and ribavirin. 
Finally, given our sample size, the associations found should 
be replicated in larger study populations.
Although physician-based guidelines for initiating antivi-
ral treatment for eligible patients with chronic HCV are based 
strongly on disease severity, individual patient preferences 
are diverse and varied. Our study highlights the association 
of both disease severity and patient choice predisposition 
with initiation of antiviral treatment.   Elucidating the specific 
modifiable patient characteristics that determine choice pre-
disposition at the time of discussion of antiviral treatment 
will be pivotal to optimizing treatment initiation rates in all 
patients. This is particularly important in patients with more 
severe disease who are most likely to benefit from treatment. 
Our study also highlights the importance of addressing sys-
temic barriers to treatment. This is true even for systems that 
prioritize access, such as the VA. However, despite efforts 
to increase initiation rates, the high discontinuation rate in 
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Table 5B Associations between subject characteristics (continuous) and completion of treatment
Characteristic All patients median (range) P value
Subjects completing  
treatment (N = 24)
Subjects not completing  
treatment (N = 121)
Age (years) 51 (29–64) 52 (26–64) 1.0
Social support scorea 67 (18–100) 60 (18–100) 0.54
HCV-related quality of lifeb 34 (0–77) 18 (0–77) 0.27
Trust in physicianc 67 (45–98) 77 (48–100) 0.08
Choice predispositiond 10 (4–10) 10 (5–10) 0.84
Notes: aBased on a previously validated social support scale consisting of 18 questions. Range of total score is 0–100 with higher scores representing greater social support; 
bbased on a previously validated hepatitis C (HCV) quality of life scale encompassing eleven questions. range of total score is 0–100 with higher scores representing worse 
quality of life; cbased on a previously validated trust in physician scale. Range of total score is 0–100 with higher scores representing greater trust in physician; dchoice 
predisposition was ascertained based on a previously validated scale ranging from zero (I am certain that I do not want to be treated) to ten (I am certain that I do want to 
be treated). Higher scores reflect greater preference towards undergoing treatment.
our population underscores the importance of developing 
newer therapies with more favorable toxicity and efficacy 
profiles. Improving treatment outcomes for patients with 
chronic HCV will require concerted efforts to (1) identify 
patients with severe disease who are reluctant to initiate 
therapy, (2) improve access for those wishing to initiate 
therapy, and most importantly, (3) develop newer therapies 
that both improve efficacy and reduce the burden of adverse 
events related to treatment.
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